Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer
- PMID: 10610624
- DOI: 10.7326/0003-4819-131-11-199912070-00002
Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer
Abstract
Background: Patients with stage II colorectal cancer and no histologic evidence of lymph node invasion develop recurrent disease, presumably because of undetected micrometastases. Guanylyl cyclase C is expressed by intestinal and colorectal cancer cells but not by extraintestinal tissues or tumors.
Objective: To examine the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer who did and did not have recurrent disease.
Design: Case-control study.
Setting: Tertiary care academic medical center.
Patients: Paraffin-embedded lymph nodes were obtained from 21 patients with histologically confirmed node-negative colorectal cancer who had undergone resection. Controls included 11 patients without disease recurrence 6 or more years after resection, and case-patients included 10 patients whose disease recurred up to 3 years after resection.
Measurements: Sections of paraffin-embedded lymph nodes were obtained from each patient and were pooled, and their RNA was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).
Results: Guanylyl cyclase C mRNA was expressed in lymph nodes from all patients with recurrent disease but not in those from patients without recurrent disease (P = 0.004). Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1 of 10 patients with recurrent disease and those from 0 of 11 patients without recurrent disease. The odds ratio for death associated with expression of guanylyl cyclase C mRNA in regional lymph nodes was 15.0 (95% CI, 1.1 to 756.7).
Conclusions: Expression of guanylyl cyclase C mRNA in lymph nodes is associated with recurrence of colorectal cancer in patients with stage II disease. Analysis of guanylyl cyclase mRNA expression by RT-PCR may be useful for colorectal cancer staging.
Similar articles
-
Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer.Dis Colon Rectum. 1998 Mar;41(3):310-5. doi: 10.1007/BF02237484. Dis Colon Rectum. 1998. PMID: 9514425
-
Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.JAMA. 2009 Feb 18;301(7):745-52. doi: 10.1001/jama.2009.141. JAMA. 2009. PMID: 19224751 Free PMC article.
-
Detection of occult metastasis in lymph nodes from colorectal cancer patients: a multiple-marker reverse transcriptase-polymerase chain reaction study.Dis Colon Rectum. 2004 May;47(5):679-86. doi: 10.1007/s10350-003-0118-2. Epub 2004 Mar 25. Dis Colon Rectum. 2004. PMID: 15037935
-
Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer.Mol Diagn Ther. 2009;13(1):11-4. doi: 10.2165/01250444-200913010-00002. Mol Diagn Ther. 2009. PMID: 19351210 Review.
-
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.Expert Rev Mol Diagn. 2005 Sep;5(5):701-13. doi: 10.1586/14737159.5.5.701. Expert Rev Mol Diagn. 2005. PMID: 16149873 Review.
Cited by
-
Inhibition of Colon Cancer Cell Growth by Phosphodiesterase Inhibitors Is Independent of cGMP Signaling.J Pharmacol Exp Ther. 2022 Apr;381(1):42-53. doi: 10.1124/jpet.121.001075. Epub 2022 Feb 2. J Pharmacol Exp Ther. 2022. PMID: 35110391 Free PMC article.
-
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.Expert Opin Ther Targets. 2021 May;25(5):335-346. doi: 10.1080/14728222.2021.1937124. Epub 2021 Jun 15. Expert Opin Ther Targets. 2021. PMID: 34056991 Free PMC article. Review.
-
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.Expert Rev Precis Med Drug Dev. 2021;6(2):117-129. doi: 10.1080/23808993.2021.1876518. Epub 2021 Feb 2. Expert Rev Precis Med Drug Dev. 2021. PMID: 34027103 Free PMC article.
-
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.Biomark Med. 2021 Feb;15(3):201-217. doi: 10.2217/bmm-2020-0359. Epub 2021 Jan 20. Biomark Med. 2021. PMID: 33470843 Free PMC article. Review.
-
An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.Expert Rev Clin Pharmacol. 2020 Oct;13(10):1125-1137. doi: 10.1080/17512433.2020.1826304. Epub 2020 Oct 6. Expert Rev Clin Pharmacol. 2020. PMID: 32945718 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical